A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases

Trial Profile

A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary) ; Temozolomide (Primary)
  • Indications Brain metastases; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Aug 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 24 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 25 Apr 2014 Planned initiation date changed from 1 Feb 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top